3-甲基-2-硝基苯甲酸乙酯 | 54064-39-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲基-2-硝基苯甲酸乙酯
• 英文名称: ethyl 3-methyl-2-nitrobenzoate
• 英文别名: 2-Nitro-3-methyl-benzoesaeure-aethylester
• CAS: 54064-39-0
• 化学式: C₁₀H₁₁NO₄
• mdl: MFCD11111006
• 分子量: 209.202
• InChiKey: GORJIFRUPPQKPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  3-甲基-2-硝基苯甲酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 potassium carbonate 作用下， 以 四氯化碳 、 乙腈 为溶剂， 反应 72.0h， 生成 ethyl 3-[(3-cyanophenoxy)methyl]-2-nitrobenzoate
  参考文献：
  名称：

  Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors

  摘要：

  Factor Xa (fXa) is a serine protease that plays a pivotal role in the coagulation cascade. High-tbroughput screening of the Yamanouchi compound library yielded lead compound I with the ability to inhibit fXa at micromolar concentrations. To improve its fXa inhibitory activity and its oral anticoagulant activity, the linker between benzamidine and the central benzene ring was modified and a carboxyl group was introduced at the central benzene ring. The resulting compounds 40b (YM-203552), 41a (YM-202054), and 41c (YM-203558) exhibited potent fXa inhibitory activity and oral anticoagulant activity. In particular, YM-203558 exhibited the most potent oral anticoagulant activity, prolonging PT more than 3-fold at 0.5 and 2.0h. Additionally, these compounds showed a high degree of selectivity for other serine proteases. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.11.005

文献信息

• Fused heterocyclic compounds, having angiotensin II antagonistic activity
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05389641A1

  公开（公告）日：1995-02-14

  Fused heterocyclic compounds of the formula (I): ##STR1## wherein R.sup.1 is an optionally substituted hydrocarbon residue which may be attached through a hetero atom; R.sup.2 is a group capable of forming an anion or a group convertible thereinto; R.sup.3 is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hetero atom; X is a direct bond or a spacer having an atomic length of two or less between the R.sup.3 group and the ring W group; W is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hereto atom; a,c and d are independently selected from the group consisting of one or two optionally substituted carbon atoms and one or two optionally substituted hetero atoms; b and e are independently selected from the group consisting of one optionally substituted carbon atom and one optionally substituted nitrogen atom wherein one of b or e must be nitrogen; the dotted line is a bond to form one double bond; n is an integer of 1 or 2 and when a, which is an optionally substituted carbon atom, is taken together with R.sup.1, the following group: ##STR2## may form a ring group; provided that when ##STR3## is a benzimidazole, thieno[3,4-d]imidazole, or thieno[2,3-d]imidazole ring, at least one of the group: ##STR4## and R.sup.3 is an optionally substituted heterocyclic residue; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.

  公式(I)的融合杂环化合物：##STR1## 其中R.sup.1是一个可选地取代的烃基团，可以通过一个杂原子连接；R.sup.2是一个能够形成阴离子或可转换成阴离子的团；R.sup.3是一个包含至少一个杂原子的可选地取代的芳香烃或杂环基团；X是R.sup.3基团和环W基团之间的直接键或原子长度为两个或更少的间隔物；W是一个包含至少一个杂原子的可选地取代的芳香烃或杂环基团；a、c和d独立地选自一个或两个可选地取代的碳原子和一个或两个可选地取代的杂原子的组；b和e独立地选自一个可选地取代的碳原子和一个可选地取代的氮原子的组，其中b或e之一必须是氮；虚线是一个形成一双键的键；n是一个1或2的整数，并且当a，即一个可选地取代的碳原子，与R.sup.1一起时，以下组：##STR2## 可以形成一个环状结构；当##STR3## 是一个苯并咪唑、噻吩[3,4-d]咪唑或噻吩[2,3-d]咪唑环时，至少一个是##STR4## 和R.sup.3的可选地取代的杂环基团；以及它们的药用可接受盐，具有强大的血管紧张素II拮抗活性和抗高血压活性，因此作为治疗循环系统疾病如高血压病、心脏病（例如心肌炎、心力衰竭、心肌梗死等）、中风、脑梗塞、肾炎等的治疗剂是有用的。
• One-pot synthesis of quinazoline-2,4(1<i>H</i>,3<i>H</i>)-diones and 2-thioxoquinazolinones with the aid of low-valent titanium reagent
  作者：Guo-Lan Dou、Man-Man Wang、Zhi-Bin Huang、Da-Qing Shi

  DOI：10.1002/jhet.121

  日期：2009.7

  An efficient, convenient, one-pot synthesis of 2,4(1H,3H)-quinazolinediones and 2-thioxoquinazolinones was accomplished in good yields via the novel reductive cyclization of ethyl 2-nitrobenzoates with isocyanates or isothiocyanates mediated by TiCl4/Zn system. J. Heterocyclic Chem., (2009).

  通过用TiCl 4 /介导的异氰酸酯或异硫氰酸酯对2-硝基苯甲酸乙酯进行新颖的还原环化反应，可以高效，方便地一锅合成2,4（1 H，3 H）-喹唑啉二酮和2-硫代氧杂喹唑啉酮。锌系统。J.杂环化​​学，（2009）。
• Process for producing(2-nitrophenyl)acetonitrile derivative and intermediate therefor
  申请人：——

  公开号：US20040199002A1

  公开（公告）日：2004-10-07

  The present invention lies in a process for producing a compound represented by the following formula [IV], which comprises the following steps (1) to (3), as well as in an intermediate therefor. (1) A step which comprises reacting a compound represented by the following formula [I] with a compound represented by the following formula [VI] or with a mixture of a compound represented by the following formula [VII] and a compound represented by the following formula [VIII] to obtain a compound represented by the following formula [IX], and hydrolyzing the compound represented by the formula [IX] under acidic conditions to obtain a compound represented by the following formula [II]. (2) A step which comprises reacting the compound represented by the formula [II] with hydroxylamine to obtain a compound represented by the following formula [III]. (3) A step which comprises dehydrating the compound represented by the formula [III] to obtain a compound represented by the formula [IV]. 1 (R 1 )(R 2 )N—CH(OR 3 )(OR 4 )   [VI] (CH 3 ) 2 N—CH(OCH 3 ) 2 [VII] (R 1 )(R 2 )NH   [VIII] 2

  本发明涉及一种制备以下化合物的方法，该化合物由以下公式（IV）表示，包括以下步骤（1）至（3），以及其中间体。 （1）一步骤包括将以下公式（I）表示的化合物与以下公式（VI）表示的化合物或以下公式（VII）表示的化合物和以下公式（VIII）表示的化合物的混合物反应，以得到以下公式（IX）表示的化合物，并在酸性条件下水解公式（IX）表示的化合物，以得到以下公式（II）表示的化合物。 （2）一步骤包括将公式（II）表示的化合物与羟胺反应，以得到以下公式（III）表示的化合物。 （3）一步骤包括脱水公式（III）表示的化合物，以得到以下公式（IV）表示的化合物。 1（R1）（R2）N—CH（OR3）（OR4）  [VI]（CH3）2N—CH（OCH3）2  [VII]（R1）（R2）NH  [VIII]
• Fused heterocyclic compounds, their production and use as angiotensin II antagonists
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1327631A2

  公开（公告）日：2003-07-16

  Fused heterocyclic compounds of the formula (I): wherein R1 is an optionally substituted hydrocarbon residue which may be attached through a hetero atom; R2 is a group capable of forming an anion or a group convertible thereinto; R3 is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hetero atom; X is a direct bond or a spacer having an atomic length of two or less between the R3 group and the ring W group; W is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hetero atom; a,c and d are independently selected from the group consisting of one or two optionally substituted carbon atoms and one or two optionally substituted hetero atoms; b and e are independently selected from the group consisting of one optionally substituted carbon atom and one optionally substituted nitrogen atom; the dotted line is a bond to form one double bond; n is an integer of 1 or 2 and when a, which is an optionally substituted carbon atom, is taken together with R1, the following group: may form a ring group; provided that when is a benzimidazole, thieno[3,4-d]imidazole, or thieno[2,3-d]imidazole ring, at least one of the group: and R3 is an optionally substituted heterocyclic residue ; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.

  式(I)的融合杂环化合物： 其中 R1 是可通过杂原子连接的任选取代的烃残基；R2 是可形成阴离子的基团或可转化为阴离子的基团；R3 是至少含有一个杂原子的任选取代的芳香烃或杂环残基；X 是 R3 基团与环 W 基团之间的直接键或原子长度为两个或更短的间隔键；W 是至少含有一个杂原子的任选取代的芳香烃或杂环残基； a、c 和 d 独立地选自由一个或两个任选取代的碳原子和一个或两个任选取代的杂原子组成的组；b 和 e 独立地选自由一个任选取代的碳原子和一个任选取代的氮原子组成的组；虚线是形成一个双键的键；n 是 1 或 2 的整数，当作为任选取代的碳原子的 a 与 R1 合在一起时，以下基团 可形成一个环状基团；但当 是苯并咪唑、噻吩并[3,4-d]咪唑或噻吩并[2,3-d]咪唑环时，至少有一个基团： 和 R3 是任选取代的杂环残基；其药学上可接受的盐类具有强效的血管紧张素 II 拮抗活性和降压活性，因此可作为治疗剂用于治疗循环系统疾病，如高血压疾病、心脏病（如心动过速、心力衰竭、心肌梗塞等）、中风、脑中风、肾炎等。
• PROCESS FOR PRODUCING (2-NITROPHENYL)ACETONITRILE DERIVATIVE AND INTERMEDIATE THEREFOR
  申请人：IHARA CHEMICAL INDUSTRY CO., LTD.

  公开号：EP1431278A1

  公开（公告）日：2004-06-23

  The present invention lies in a process for producing a compound represented by the following formula [IV], which comprises the following steps (1) to (3), as well as in an intermediate therefor. (1) A step which comprises reacting a compound represented by the following formula [I] with a compound represented by the following formula [VI] or with a mixture of a compound represented by the following formula [VII] and a compound represented by the following formula [VIII] to obtain a compound represented by the following formula [IX], and hydrolyzing the compound represented by the formula [IX] under acidic conditions to obtain a compound represented by the following formula [II]. (2) A step which comprises reacting the compound represented by the formula [II] with hydroxylamine to obtain a compound represented by the following formula [III]. (3) A step which comprises dehydrating the compound represented by the formula [III] to obtain a compound represented by the formula [IV].

  本发明涉及一种生产下式[IV]所代表的化合物的工艺，该工艺包括以下步骤（1）至（3）以及一种中间体。 (1）步骤包括将下式[I]代表的化合物与下式[VI]代表的化合物或与下式[VII]代表的化合物和下式[VIII]代表的化合物的混合物反应，得到下式[IX]代表的化合物，并在酸性条件下水解下式[IX]代表的化合物，得到下式[II]代表的化合物。 (2) 包括使式[II]代表的化合物与羟胺反应以得到下式[III]代表的化合物的步骤。 (3) 将式[III]代表的化合物脱水，得到式[IV]代表的化合物。